Patient selection, monitoring, and realistic timelines Even setting aside the regulatory reality, the clinical reasoning around growth-hormone secretagogues is more demanding than the marketing suggests and understanding it is essential context for any provider fielding patient questions
Quick Answer: Tirzepatide burning at injection site is a recognized adverse reaction occurring in approximately 3.4% of patients, typically caused by the medication's formulation pH, tissue distension, or individual sensitivity, and usually resolves spontaneously within minutes to hours
Second, although there is abundant evidence from basic research, there is still a significant evidence gap in clinical trials targeting populations, lacking large sample size data to support efficacy and safety
While our results are consistent with a senolytic effect of GPX4 inhibitors, the effects observed in some of the models, although significant, were modest, and we acknowledge that further investigation is needed to assess a potential translation to the clinic
But tirzepatide is not aspirin
